Antar SA,Ashour NA,Sharaky M,Khattab M,Ashour NA,Zaid RT .2023 .Diabetes mellitus: Classification, mediators, and complications; A gate to identify potential targets for the development of new effective treatments. Biomed Pharmacother, 168 : 115734.
Maric-Bilkan C .2013 .Obesity and diabetic kidney disease. Med Clin North Am, 97 : 59-74.
Than WH,Chan GC,Ng JK,C-C. JK .2020 .The role of obesity on chronic kidney disease development, progression, and cardiovascular complications. Adv Biomark Sci Technol, 2 : 24-34.
Sattar N,Presslie C,Rutter MK,McGuire DK .2024 .Cardiovascular and Kidney Risks in Individuals With Type 2 Diabetes: Contemporary Understanding With Greater Emphasis on Excess Adiposity. Diabetes Care, 47 : 531-43.
Sizar O,Podder V,Talati R.,Empagliflozin R. .2018 .. , : .
Yadav J,Ahsan F,Panda P,Mahmood T,Ansari VA,Shamim A,Empagliflozin-A Sodium Glucose A .2024 .Cotransporter-2 Inhibitor: Overview of its Chemistry, Pharmacology, and Toxicology. Curr. Diabetes Rev, 20 : 30-52.
Hedrington MS,Davis SN .2015 .The role of empagliflozin in the management of type 2 diabetes by patient profile. Ther Clin Risk Manag, : 739-49.
Dutta S,Shah RB,Singhal S,Dutta SB,Bansal S,Sinha S .2023 .Metformin: A review of potential mechanism and therapeutic utility beyond diabetes. Drug Des Dev Ther, : 1907-32.
Hostalek U,Campbell I .2021 .Metformin for diabetes prevention: update of the evidence base. Curr Med Res Opin, 37 : 1705-17.
Goldman JD .2018 .Combination of Empagliflozin and Metformin Therapy: A Consideration of its Place in Type 2 Diabetes Therapy. Clin Med Insights Endocrinol Diabetes, 11 : 1-11.
Triplitt C,Solis-Herrera C,Cersosimo E,Abdul-Ghani M,Defronzo RA .2015 .Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus. Expert Opin Pharmacother, 16 : 2819-33.
Leenders M,Verdijk LB,van der Hoeven L,Adam JJ,van Kranenburg J,Nilwik R .2013 .Patients With Type 2 Diabetes Show a Greater Decline in Muscle Mass, Muscle Strength, and Functional Capacity With Aging. J Am Med Dir Assoc, 14 : 585-92.
Pereira MJ,Eriksson JW .2019 .Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity. Drugs, 79 : 219-30.
Cuatrecasas G,De Cabo F,Coves MJ,Patrascioiu I,Aguilar G,Cuatrecasas G .2024 .Dapagliflozin added to metformin reduces perirenal fat layer in type 2 diabetic patients with obesity. Sci Rep, 14 : 10832.
Cho YK,Kim Y-J,Jung CH .2021 .Effect of sodium-glucose cotransporter 2 inhibitors on weight reduction in overweight and obese populations without diabetes: a systematic review and a meta-analysis. J Obes Metab Syndr, 30 : 336.
Ferreira-Hermosillo A,Molina-Ayala MA,MolinaGuerrero D,Garrido-Mendoza AP,Ramírez-Rentería C,Mendoza-Zubieta V .2020 .Efficacy of the treatment with dapagliflozin and metformin compared to metformin monotherapy for weight loss in patients with class III obesity: a randomized controlled trial. Trials, 21 : 186-9.
Foley JE,Jordan J .2010 .Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience. Vasc Health Risk Manag, 6 : 541-8.
Gilbert MP,Pratley RE .2020 .GLP-1 analogs and DPP-4 inhibitors in type 2 diabetes therapy: review of head-tohead clinical trials. Front Endocrinol, 11 : 178-82.
Scheen AJ .2016 .DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects. Expert Opin Drug Metab Toxicol, 12 : 1407-17.
Min SH,Yoon J-H,Moon SJ,Hahn S,Cho YM .2018 .Combination of sodium-glucose cotransporter 2 inhibitor and dipeptidyl peptidase-4 inhibitor in type 2 diabetes: a systematic review with meta-analysis. Sci Rep, 8 : 4466-9.
Molina-Vega M,Muñoz-Garach A,Fernández-García JC .2018 .The safety of DPP-4 inhibitor and SGLT2 inhibitor combination therapies. Expert OPion Drug Safety, 17 : 815-24.
Scheen AJ .2018 .The safety of empagliflozin plus metformin for the treatment of type 2 diabetes. Expert Opin Drug Saf, 17 : 837-48.
Ahmed I,Raja UY,Wahab MU,Rehman T,Ishtiaq O,Aamir AH .2022 .Efficacy and safety of combination of empagliflozin and metformin with combination of sitagliptin and metformin during Ramadan: an observational study. BMC Endocr Disord, 22 : 247.
Hadjadj S,Rosenstock J,Meinicke T,Woerle HJ,Broedl UC .2016 .Initial Combination of Empagliflozin and Metformin in Patients with Type 2 Diabetes. Diabetes Care, 39 : 1718-28.